NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 116 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $435,306 | -50.0% | 406,828 | +20.9% | 0.00% | -50.0% |
Q2 2023 | $871,364 | -37.6% | 336,434 | -1.6% | 0.00% | -50.0% |
Q1 2023 | $1,395,450 | -0.4% | 342,022 | +22.5% | 0.00% | 0.0% |
Q4 2022 | $1,401,534 | -58.8% | 279,190 | +7.4% | 0.00% | -66.7% |
Q3 2022 | $3,400,000 | +57.0% | 259,940 | +53.9% | 0.01% | +71.4% |
Q2 2022 | $2,166,000 | -3.5% | 168,920 | +14.8% | 0.01% | 0.0% |
Q1 2022 | $2,245,000 | -46.4% | 147,198 | -37.8% | 0.01% | -22.2% |
Q4 2021 | $4,191,000 | -4.3% | 236,659 | +13.6% | 0.01% | -10.0% |
Q3 2021 | $4,379,000 | +1498.2% | 208,320 | +1398.7% | 0.01% | +900.0% |
Q2 2021 | $274,000 | -86.2% | 13,900 | -79.6% | 0.00% | -80.0% |
Q1 2021 | $1,981,000 | +151.4% | 68,147 | +37.6% | 0.01% | +66.7% |
Q3 2020 | $788,000 | -18.3% | 49,542 | +1.5% | 0.00% | -40.0% |
Q2 2020 | $964,000 | – | 48,815 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |